
STAT+: Pharmalittle: We’re reading about a controversial FDA pick, a Trump drug-pricing plan, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far so we are determined to hang on for another couple of days. And why not? The alternatives — …